Major Depressive Disorder (DSM-V) – Unmet Need – Unmet Need – Treatment-Resistant Depression (US/EU)
Major depressive disorder (MDD) is typically treated with psychotherapy, pharmacotherapy, or a combination of the two. The MDD therapy market is highly genericized; for patients experiencing treatment-resistant depression (TRD), these standard therapies may be ineffective. While branded agents such as Lundbeck / Takeda’s Trintellix / Brintellix (vortioxetine) and Johnson & Johnson Innovative Medicine’s Spravato (esketamine) and antipsychotics used as adjuncts to an antidepressant have expanded treatment options, opportunity remains for new drugs better able to manage TRD. Agents currently in development, including psychedelics, may help fill this need. This report provides quantitative insight into psychiatrists’ perceptions of key treatment drivers and goals and assesses the current level of unmet need and opportunity in the treatment of TRD.
Questions answered
- Which clinical / nonclinical attributes drive psychiatrists’ decision making in the treatment of TRD, which have limited impact, and which are hidden opportunities?
- How do psychiatrists rate the performance of key current therapies on treatment drivers and goals for TRD?
- What is the relative level of need for improved treatment options in multiple psychiatry indications, including TRD?
- Based on a conjoint analysis and TPP simulation, what trade-offs between efficacy, safety, convenience of administration, and price are psychiatrists willing to make for a hypothetical new MDD therapy?
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Key feature:
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European psychiatrists fielded in September 2024
Key companies: Otsuka Pharmaceutical, Lundbeck, AbbVie, Recordati, Takeda, Johnson & Johnson Innovative Medicine, Compass Pathways
Key drugs: aripiprazole, Vraylar / Reagila, Spravato, Trintellix / Brintellix, bupropion, Symbyax / olanzapine + fluoxetine
